AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1958438
Drug: ICI 169,369
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 169,369 (80 mg)
Trial: 1958438
Drug: ICI 169,369
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 169,369 (120 mg)
Trial: 6752042
Drug: Placebo treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment, control group
Trial: 31044748
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg/day plus telbivudine (LDT) 600 mg/day
Trial: 28710224
Drug: 3-month automated
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month automated closed-loop insulin delivery combined with pump suspend feature
Trial: 23406253
Drug: Topical medications
RxNorm normalized name: Procto-Med Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical medications with percentage IOP reduction >22.1%
Trial: 23406253
Drug: Topical medications
RxNorm normalized name: Procto-Med Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical medications with percentage IOP reduction
Trial: 28389316
Drug: Vinflunine (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinflunine (320 mg/m2 or 280 mg/m2 every 21 days)
Trial: 21420121
Drug: Laser acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser acupuncture therapy
Trial: 3311119
Drug: Antibiotic regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic regimen
Trial: 6110915
Drug: Oestrogen treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen treatment
Trial: 27049176
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (no theophylline)
Trial: 24755136
Drug: Lorazepam 1
RxNorm normalized name: lorazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 1 mg before sleep with noise exposure
Trial: 24755136
Drug: Control (Lorazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Lorazepam 1 mg before sleep without noise exposure)
Trial: 18331216
Drug: Calcium carbasalate
RxNorm normalized name: carbasalate calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium carbasalate (380 mg/day)
Trial: 18331216
Drug: Acetazolamide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (500 mg/day)
Trial: 12763518
Drug: Low-dose HRT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose HRT
Trial: 1289923
Drug: S-adenosyl-L-methionine (SAMe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine (SAMe) 200 mg/day intramuscularly
Trial: 6377145
Drug: Low-dose prostaglandin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prostaglandin E2 vaginal gel
Trial: 15801915
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment
Trial: 31245006
Drug: High-dose behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose behavioral treatment (24 sessions)
Trial: 31245006
Drug: Moderate-dose behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dose behavioral treatment (16 sessions)
Trial: 30348537
Drug: Genotype-guided dosing
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided dosing
Trial: 24657555
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment using RPDs
Trial: 19395186
Drug: RT (radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT (radiation therapy)
Trial: 17319791
Drug: Anthracycline therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline therapy (PA)
Trial: 17319791
Drug: Different antitumor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different antitumor drugs (P0)
Trial: 9095608
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl and bupivacaine (group I)
Trial: 8455424
Drug: No prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No prednisolone pretreatment followed by interferon therapy
Trial: 8455424
Drug: Clinical relapse
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical relapse after therapy
Trial: 3094355
Drug: Nicardipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (30 or 40 mg 3 times daily)
Trial: 12877448
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray 200 microg used as needed (FP200PRN)
Trial: 1929293
Drug: Cefonicid (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefonicid (1 g, single dose)
Trial: 1929293
Drug: Clindamycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (600 mg, every 8 h for a total of four doses)
Trial: 31401841
Drug: Zumba intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zumba intervention (twice-weekly group classes)
Trial: 31112475
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (n = 211)
Trial: 26017129
Drug: Multifaceted quality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted quality improvement intervention with a daily checklist, definition of daily care goals during multidisciplinary daily rounds, and clinician prompts.
Trial: 21506633
Drug: Multimodal behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal behavior treatment (MBT) with hand massage
Trial: 21506633
Drug: Multimodal behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal behavior treatment (MBT) without hand massage
Trial: 20799476
Drug: IVN201 (functional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVN201 (functional fusion peptide) administered via intralymphatic immunotherapy (ILIT)
Trial: 22155903
Drug: Carraguard gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carraguard gel
Trial: 12043953
Drug: Extended-release glipizide
RxNorm normalized name: glipizide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release glipizide GITS (Glucotrol XL) 20 mg once daily
Trial: 7737631
Drug: Intravenous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous octreotide (25-micrograms bolus)
Trial: 7737631
Drug: Intravenous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous octreotide (infusion of 50-micrograms/hr)
Trial: 1478163
Drug: Cefaclor 250
RxNorm normalized name: cefaclor 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor 250 mg
Trial: 19690618
Drug: Chlorproguanil-dapsone-artesunate (CDA)
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Chlorproguanil-dapsone-artesunate (CDA) 2/2.5/4 mg/kg once daily for three days (N = 914)
Trial: 24359312
Drug: Intradermal locator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal locator device
Trial: 16154851
Drug: Erythropoietin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin at a dose of 500 U/kg/week s.c.
Trial: 10357495
Drug: Immediate zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate zidovudine (AZT) treatment
Trial: 10357495
Drug: Deferred zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferred zidovudine (AZT) treatment
Trial: 10357495
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of didanosine (ddI)
Trial: 8963481
Drug: Coated levomepromazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coated levomepromazine tablets
Trial: 8963481
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion (reference)
Trial: 1903663
Drug: High energy
RxNorm normalized name: High energy formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High energy neutron treatment
Trial: 1903663
Drug: Conventional megavoltage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional megavoltage x ray treatment (photon treatment)
Trial: 28298041
Drug: IV ibuprofen,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ibuprofen, scheduled oral acetaminophen, and rescue opioids
Trial: 28298041
Drug: IV placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo, scheduled oral acetaminophen, and rescue opioids
Trial: 29617523
Drug: Enalapril, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril, 10 mg twice daily
Trial: 26821227
Drug: Dexamethasone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (2 mg/day for 2 days)
Trial: 26821227
Drug: Fish Oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish Oil (840 mg/day of EPA + DHA for 3 weeks) with Dexamethasone
Trial: 21789658
Drug: Self‐administered questionnaires
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐administered questionnaires
Trial: 26985729
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) alone for 15 sessions
Trial: 26985729
Drug: Motivational Interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Interviewing (MI) followed by Cognitive-Behavioral Therapy (CBT) integrated with MI (4 MI sessions + 11 CBT sessions)
Trial: 20473737
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine therapy (Kunbao Pill and Modified Xiaoyao Pill)
Trial: 20473737
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Chinese medicine therapy + psychological intervention)
Trial: 15703770
Drug: IC-PGE1 +
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IC-PGE1 + 50 mg sildenafil
Trial: 19157723
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy
Trial: 23722581
Drug: Intradermal sutures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal sutures
Trial: 30087427
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose PORT (>66.60 cGy)
Trial: 30087427
Drug: Very high
RxNorm normalized name: Very high density lipoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very high dose PORT (>70.20 cGy)
Trial: 22745114
Drug: D5W-LA group
RxNorm normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D5W-LA group (6 mL of D5W followed by 6 mL of lidocaine 1.5% with epinephrine 1:200,000)
Trial: 22745114
Drug: LA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LA group (6 mL of lidocaine 1.5% with epinephrine 1:200,000 alone)
Trial: 2656736
Drug: Cabergoline 0.2-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.2-1 mg once weekly
Trial: 2656736
Drug: Cabergoline 0.2-0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.2-0.5 mg twice weekly
Trial: 25727860
Drug: Sildenafil 20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 20, 40 or 80 mg three times daily
Trial: 18579168
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.03 g/kg/day)
Trial: 8694085
Drug: Rimexolone 1%
RxNorm normalized name: RIMEXOLONE 1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimexolone 1% ophthalmic suspension
Trial: 10686218
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg testosterone alone (T; n = 11)
Trial: 8374686
Drug: rhGH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH therapy administered 3 times a week with a total weekly dose of 0.5 IU/kg
Trial: 8374686
Drug: rhGH therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH therapy administered 6 times a week with a total weekly dose of 0.5 IU/kg
Trial: 3529360
Drug: 1 week
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 week of cimetidine treatment followed by 3 weeks of placebo (C1 + P)
Trial: 28328086
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment condition (EXP; N = 11)
Trial: 28328086
Drug: Treatment-as-usual control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual control condition (TAU; N = 10)
Trial: 26439386
Drug: OFD +
RxNorm normalized name: OFDZ
DrugBank: Oxfendazole (DB11446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OFD + placebo gel (group 1)
Trial: 26439386
Drug: 1.2 mg
RxNorm normalized name: RNA 1.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg RSV gel + PRF + HA with OFD (group 3)
Trial: 25089930
Drug: Sequential fluoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential fluoxetine
Trial: 15793249
Drug: Pramlintide (30-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide (30-45 microg) with usual insulin bolus-to-carbohydrate ratio
Trial: 10630070
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of mesoglycan (1 or 2 vials/day)
Trial: 2127834
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg twice daily for 28 days
Trial: 7194395
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 150 ml/kg per day
Trial: 27810317
Drug: XG-102 900
RxNorm normalized name: Ninjacof XG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XG-102 900 μg
Trial: 27810317
Drug: XG-102 90
RxNorm normalized name: Ninjacof XG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XG-102 90 μg
Trial: 23695545
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (omeprazole 20 mg bid + amoxicillin 1 g bid for 5 days, followed by omeprazole 20 mg bid + tinidazole 500 mg bid + clarithromycin 500 mg bid for an additional 5 days)
Trial: 21292420
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE) therapy for an average of 6.6 years
Trial: 21292420
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (nonusers of CEE therapy)
Trial: 11379675
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg ropivacaine
Trial: 11379675
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg ropivacaine plus 75 microg clonidine
Trial: 11379675
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg ropivacaine plus 15 microg clonidine
Trial: 11379675
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg ropivacaine plus 45 microg clonidine
Trial: 8351757
Drug: Maintenance Bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance Bacillus Calmette‐Guérin (BCG) therapy with 20 intravesical instillations in 1 year
Trial: 8351757
Drug: Maintenance Bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance Bacillus Calmette‐Guérin (BCG) therapy with 20 intravesical instillations in 1 year and 6 intradermal inoculations
Trial: 8351757
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no intradermal inoculations)
Trial: 10720032
Drug: Vehicle infusion
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle infusion
Trial: 26119203
Drug: Percutaneous interspinous
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous interspinous process spacer (IPS) treatment
Trial: 15481651
Drug: antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antidepressants
Trial: 11747248
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg of inhaled salbutamol (Albuterol) from the original Glaxo product
Trial: 11747248
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg of inhaled salbutamol (Albuterol) from generic product 1
Trial: 11747248
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg of inhaled salbutamol (Albuterol) from generic product 2
Trial: 20645509
Drug: Isobaric 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric 0.5% bupivacaine (3 ml)
Trial: 20645509
Drug: Hyperbaric 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric 0.5% bupivacaine (3 ml)
Trial: 30897585
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (20 min before, during, and 20 min after endotracheal suctioning)
Trial: 27247511
Drug: Saline (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (normal saline infusion)
Trial: 26825757
Drug: modified WHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified WHO ORS with PHGG 15 g/L
Trial: 16943652
Drug: Hypothermia therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermia therapy for 24 hours
Trial: 14578238
Drug: DOIT (Diabetes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOIT (Diabetes Outpatient Intensive Treatment program)
Trial: 10343151
Drug: tolcapone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolcapone (200 mg)
Trial: 1929509
Drug: Ibuprofen 5
RxNorm normalized name: ibuprofen 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 5 mg/kg
Trial: 7707120
Drug: IFN/5‐FU (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN/5‐FU (9 MIU interferon alfa-2a subcutaneously three times per week, 5‐FU 750 mg/m2/d by continuous intravenous infusion on days 1 to 5, then weekly i.v. bolus)
Trial: 7707120
Drug: LV/5‐FU (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV/5‐FU (200 mg/m2/d leucovorin by i.v. infusion plus 5‐FU 370 mg/m2/d by i.v. bolus on days 1 to 5, repeated every 4 weeks)
Trial: 2533034
Drug: Conventional injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional injection therapy
Trial: 30928279
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (E2) treatment for 1 week
Trial: 28472101
Drug: Placebo (PL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL) treatment for 1 week
Trial: 1982764
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg) with piroxicam (40 mg)
Trial: 30650232
Drug: Overall Compliance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall Compliance in TAIL treatment
Trial: 30650232
Drug: Specific Compliance
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific Compliance in TAIL treatment
Trial: 25039889
Drug: Aliskiren (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (150 mg) added to valsartan (80 mg)
Trial: 25039889
Drug: Valsartan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (80 mg) alone
Trial: 16275826
Drug: Surrogate consent
RxNorm normalized name: Consensi
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surrogate consent for randomized clinical trials of new medications
Trial: 14605518
Drug: Standard pharmacologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacologic therapy
Trial: 8523341
Drug: Deflazacort 24
RxNorm normalized name: Deflazacort 24 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deflazacort 24 mg/day